Lab Monitoring for Polymyalgia Rheumatica

Baseline Laboratory Assessment

• The European League Against Rheumatism recommends obtaining a comprehensive baseline laboratory panel, including inflammatory markers, complete blood count, metabolic panel, bone profile, urinalysis, and rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies, to exclude mimicking conditions and establish monitoring parameters 1
• A baseline laboratory panel should include essential tests such as C-reactive protein, erythrocyte sedimentation rate, complete blood count, metabolic panel, bone profile, urinalysis, and rheumatoid factor and/or anti-cyclic citrullinated peptide antibodies to assess disease activity and exclude alternative diagnoses 1

Ongoing Monitoring Schedule

• The American College of Rheumatology recommends monitoring patients with clinical and laboratory assessments every 4-8 weeks during the first year, every 8-12 weeks during the second year, and as indicated during relapses or dose tapering 2, 1
• Patients should be monitored for inflammatory markers, such as ESR and/or CRP, to assess disease activity, as well as clinical disease activity measures, including pain scores, morning stiffness duration, and functional status 2

Key Monitoring Considerations

• The European League Against Rheumatism suggests that an ESR >40 mm/hr at baseline is associated with higher relapse rates, highlighting the importance of close monitoring 1
• Patients on glucocorticoid therapy should be screened for diabetes, hypertension, osteoporosis, glaucoma, and cardiovascular disease, as these comorbidities increase the risk of glucocorticoid adverse effects 1, 4
• Female patients have a higher risk of glucocorticoid-related side effects and should be monitored more closely, with documentation of comorbidities and concomitant medications at each visit 1, 2

Common Pitfalls to Avoid

• The American College of Rheumatology recommends ensuring adequate monitoring frequency, as less frequent monitoring than recommended may miss relapses or adverse effects requiring intervention 2
• Patients should be monitored for signs of relapse, including recurrence of shoulder/hip pain and elevated inflammatory markers, to guide treatment decisions 2